PR Newswire BiotechOriginal article
MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity
Phase 1positiveDA-1726Positive
AI Analysis
Summary
MetaVia announced successful completion of dose titration in Phase 1 Part 3 study of DA-1726, with all active patients reaching target doses of 48 mg and 64 mg. Topline data readout remains on track for Q4 2026.
Clinical Trial Data
Phase
Phase 1 Part 3
Primary Endpoint
Met
Outcome Details
All active patients in both cohorts successfully reached highest target doses of 48 mg and 64 mg
Importance:5/10
Sentiment:
0.70
obesitydose titrationclinical trialPhase 1topline data
Related Companies
Read the original article
Published by PR Newswire Biotech on July 9, 2026 12:31 PM